UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):
May 29, 2007
GENZYME CORPORATION
(Exact name of registrant as specified in its charter)
Massachusetts | | 0-14680 | | 06-1047163 |
(State or other jurisdiction of incorporation or organization) | | (Commission file number) | | (IRS employer identification number) |
500 Kendall Street, Cambridge, Massachusetts 02142
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code:
(617) 252-7500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On May 29, 2007, Genzyme Corporation issued a press release announcing that its Board of Directors has authorized the Company to repurchase up to $1.5 billion or 20 million shares of its outstanding common stock over a three year period. A copy of the press release is included as Exhibit 99.1 and incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No. | | Description | |
99.1 | | Press release of Genzyme Corporation dated May 29, 2007. Filed herewith. | |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | GENZYME CORPORATION | |
| | | |
Dated: May 29, 2007 | | By: | /s/ Michael S. Wyzga |
| | | Michael S. Wyzga |
| | | Executive Vice President and |
| | | Chief Financial Officer |
| | | | |
3
EXHIBIT INDEX
Exhibit No. | | Description | |
99.1 | | Press release of Genzyme Corporation dated May 29, 2007. Filed herewith. | |
4
